Ocuphire Pharma

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Three ASCRS presentations will feature data from Nyxol® clinical studies: second Phase 3 MIRA-3 trial (reversal of mydriasis) and Phase 2 VEGA-1 trial (presbyopia) Three ASCRS presentations will feature data from Nyxol® clinical studies: second Phase 3 MIRA-3 trial (reversal of mydriasis) and Phase 2 VEGA-1 trial (presbyopia)

Ocuphire Appoints Jay Pepose, M.D., Ph.D., as Chief Medical Advisor and Announces Upcoming Presentations at ASCRS 2022 and Eyecelerator

FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, MBA, Founder and CEO, will review the opportunity for APX3330, a Phase 2b oral small molecule inhibitor of novel target Ref-1 in diabetic eye disease at the Wet AMD & DME Drug Development Summit today, Wednesday, April 6 in Boston, MA. Ms. Sooch will also participate in a panel discussion titled, “The Race to Market Share: Is the answer ending the burden of monthly treatments?” Mitch Brigell, Ph.D., Head of Clinical Development and Strategy at Ocuphire, will moderate a panel discussion on “Future Therapies Targeting Novel Mechanisms Driving Wet AMD & DME” at the Summit.

Ocuphire Pharma to Present at Wet AMD & DME Drug Development Summit in Boston, MA

Ocuphire Pharma Inc (NASDAQ: OCUP) announced topline results from the second Phase 3 MIRA-3 trial of Nyxol to reverse pharmacologically-induced mydriasis (dilation of the pupil).  The trial met its primary endpoint, with 58% of subjects (study eye) treated with Nyxol returning.

Ocuphire Pharma's Shares Fall Despite Positive Data From Registrational Phase 3 Trial Of Nyxol

Meets Primary Endpoint With 58% Of Nyxol treated Subjects Returning to Baseline Pupil Diameter at 90 Minutes Compared to 6% of Placebo Subjects (p

Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial Data Catalysts in 2022:– Nyxol ® MIRA-3 Phase 3 Results Expected End of 1Q 2022–  MIRA-4 Pediatric, and LYNX-1 Phase 3 Results Expected to follow in 2Q 2022–  ZETA-1 Phase 2 Diabetic Retinopathy Results Expected in 2H 2022

Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update

Successful Execution and Completion of Enrollment in Four Late-Stage Clinical Trials Across Nyxol and APX3330 Programs in First Quarter of 2022

Ocuphire Completes Enrollment of Over 100 Subjects in 24-Week ZETA-1 Phase 2b Trial of Oral APX3330 for the Treatment of Diabetic Retinopathy

FARMINGTON HILLS, Mich., March 10, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, MBA, Founder and CEO will present a corporate overview at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16 at 8:00-8:30 AM EDT.

Ocuphire Pharma to Present at Oppenheimer Annual Healthcare Conference

With Growing Rate of Childhood Myopia, MIRA-4 Trial Supports a Potential Broader RM Label for Nyxol in Pediatric Subjects 3 to 11 Years

Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

Completed enrollment ahead of schedule in second Phase 3 FDA registration trial for Nyxol in RM (MIRA-3) with top-line results expected soon around the end of 1Q22

Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations

New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia

Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day

Update on Late-Stage Clinical Trials in the APX3330 and Nyxol Programs as well as Commercial Insights for Nyxol for RM and Presbyopia by Six Leading KOLs

Ocuphire to Host Virtual Investor R&D Day on January 31st

Completed Enrollment of Nyxol ® LYNX-1 Phase 3 NVD Trial

Ocuphire Provides Corporate Update: Announcing Enrollment Completion of Phase 3 Nyxol Trial, Enrollment Initiation of Nyxol Pediatric Trial, and an Investor R&D Day in January

FARMINGTON HILLS, Mich, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that it has appointed six new key opinion leaders (KOLs) across retina, refractive surgery, and optometry to its Medical Advisory Board (MAB).

Ocuphire Expands Prestigious Medical Advisory Board with Six New KOLs to Support Advancement of Late-Stage Ophthalmic Assets Nyxol® and APX3330

The stock price of Ocuphire Pharma Inc (NASDAQ: OCUP) increased by over 65% pre-market today. This is why it happened.

Ocuphire Pharma (OCUP) Stock: Why The Price Surged Today

RM Indication Allows for Rapid Recruitment with Top-line Results Expected in Early 2022

Ocuphire Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis (RM)

Ocuphire Pharma, Inc. (OCUP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Ocuphire Pharma, Inc. (OCUP) Loses 17.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022

Ocuphire Invited to Present Clinical Data on Nyxol® and APX3330 at the American Academy of Ophthalmology 2021 Annual Meeting and Eyecelerator/AAO Meeting

New Review Publications Underscore the Role of the APE1/Ref-1 Protein in Multiple Pro-angiogenic Pathways Associated with Neovascular Eye Disease Including Diabetic Retinal Diseases and Age-Related Macular Degeneration

Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases

FARMINGTON HILLS, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that its clinical-stage, novel oral Ref-1 inhibitor, APX3330, for the treatment of diabetic retinal disease will be featured at the Ophthalmology Innovation Summit (OIS) Retina@ASRS Innovation Company Showcase on October 7 in San Antonio, TX. The APX3330 abstract was accepted for podium presentation and discussion at the 39th Annual Meeting of the American Society of Retina Specialists (ASRS), to take place October 8 – 12 in San Antonio, TX.

Ocuphire's Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meeting

Euro Forums 2021 Virtual Retina Forum on September 8, 2021

Ocuphire Pharma Presenting at Four Conferences in September

Continued Momentum in Nyxol ® Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia

Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update

Canaccord Genuity 41 st Annual Growth Conference being held virtually on August 10-12, 2021

Ocuphire Pharma Presenting at Two Conferences in August

Ocuphire is positioning itself as a leading ophthalmic player, providing novel therapeutic solutions for both front and back of the eye indications.

Ocuphire Pharma: An Undervalued Ophthalmic Play

Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal Diseases

Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021 ASCRS Annual Meeting in Las Vegas

News for Ocuphire Pharma Stock (OCUP)